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Abstract 
Raloxifene exhibits quite a large and unexplained interindividual variability in its 
pharmacokinetics and pharmacodynamics. The aim of our study was to identify transporters 
involved in the efflux of raloxifene and its glucuronide metabolites by various in vitro models 
and by an in vivo study to explore the possible involvement of Pgp, MRP1, MRP2, MRP3, 
and BCRP in the observed high interindividual variability. Experiments with PAMPA 
(Parallel Artificial Membrane Permeability Assay) showed the highest passive permeability 
for raloxifene, followed by raloxifene-6-β-glucuronide (M1), raloxifene-4'-β-glucuronide 
(M2) and raloxifene-6,4'-diglucuronide (M3). Caco-2 cell monolayer experiments indicated 
an interaction of raloxifene with Pgp. The ATPase assay confirmed the raloxifene interaction 
with Pgp, and also indicated interactions of all raloxifene species with MRP1, MRP2, MRP3 
and BCRP, except for M1 which did not show any interactions with MRP2. Furthermore, the 
vesicular experiments confirmed the interaction of M2 and M3 with MRP2. Although the in 
vivo study on osteoporotic postmenopausal women on raloxifene could not confirm a 
significant influence of ABCB1 and ABCC2 genetic polymorphisms on its pharmacokinetics, 
a clear trend towards higher total raloxifene concentrations was observed in carriers of at least 
one ABCB1 c.3435T allele. Moreover, the same polymorphism effect was also observed as a 
significant increase in total hip bone mineral density after 1 year of treatment. In conclusion, 
the results of our study support the involvement of efflux transporters in disposition of 
raloxifene and its metabolites and may partially explain the observed raloxifene variability by 
the influence of the ABCB1 c.3435C>T polymorphism.  
 
Keywords: raloxifene, efflux transporters, genetic polymorphisms, pharmacokinetics, 
pharmacodynamics, translation 
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Running head and abbreviations 
Running head: Efflux transporters and raloxifene  
Abbreviations: ABC transporters, ATP-binding cassette transporters; ABCB1, ATP-binding 
cassette transporter B1 gene (Pgp); ABCC2, ATP-binding cassette transporter C2 gene 
(MRP2);  BALP, serum bone-specific alkaline phosphatase; BCRP, breast cancer resistance 
protein; BMD, bone mineral density; BMD-FN, bone mineral density of femoral neck; BMD-
HIP, bone mineral density of total hip; BMD-LS, bone mineral density of lumbar spine L1-
L4; BSEP, bile salt export pump; BUA, broadband ultrasound attenuation; CTX, serum C-
terminal telopeptide fragments of type I collagen; DMSO, dimethylsulfoxide; E17βG , 
estradiol-17β-glucuronide; FA, formic acid; FLU, fluorescein; FumC, fumitremorgin C; LC-
MS/MS, liquid chromatography - tandem mass spectrometry; M1, raloxifene-6-β-
glucuronide; M2, raloxifene-4'-β-glucuronide; M3, raloxifene-6,4'-diglucuronide; MRP, 
multidrug resistance-associated protein; OC, osteocalcin; PAMPA, parallel artificial 
membrane permeability assay; Pgp, P-glycoprotein; QUI, quantitative ultrasound index; SNP, 
single nucleotide polymorphism; SOS, heel speed of sound; UGTs, UDP-
glucuronosyltransferases.
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Introduction 
ATP-binding cassette (ABC) transporters work in concert to control the bioavailability of 
drugs and are thus important determinants of drug-drug interactions, drug efficacy and 
toxicity. P-glycoprotein (Pgp), multidrug resistance-associated proteins (MRPs), breast cancer 
resistance protein (BCRP) and bile salt export pump (BSEP) are efflux transporters, which 
have been well characterized for their ability to transport xenobiotics and endobiotics [1, 2].  
Raloxifene, a selective estrogen receptor modulator, is approved worldwide for the prevention 
and treatment of postmenopausal osteoporosis and for the prevention of breast cancer in 
postmenopausal women. Raloxifene therapy suppresses the bone turnover to normal 
premenopausal range, thereby increasing bone mineral density (BMD) in the spine, hip and 
total body [3, 4], reducing the risk for vertebral fractures [5] but not changing non-vertebral 
fracture risk [6]. After peroral application, raloxifene undergoes a rapid absorption, an 
extensive first-pass metabolism and an entero-hepatic cycling. According to the estimations, 
the fraction of raloxifene absorbed is high, 60 %, but only 2% reaches the systemic circulation 
in unconjugated form due to the high metabolic turnover during absorption [7]. The rest 
represents raloxifene conjugated by UDP-glucuronosyltransferases (UGTs) to raloxifene-4'-β-
glucuronide (M2), raloxifene-6-β-glucuronide (M1) [7, 8] and raloxifene-6,4'-diglucuronide 
(M3) [7, 9]. Although the glucuronides show little affinity for the estrogen receptors and for 
bone tissue, they are important because they can be readily reconverted back into active 
raloxifene in various organs by β-glucuronidases residing in the liver, lung, spleen, kidney, 
bone and uterus [10]. Raloxifene and its metabolites are primarily excreted in feces and less 
than 0.2% and 6% of raloxifene and its metabolites, respectively, are recovered in urine [7]. 
This fact, coupled with the observation of a major entero-hepatic cycling, suggests an 
important role of efflux transporters located in the canalicular membrane of hepatocytes 
and/or in the brush border membrane of intestinal epithelial cells. Previous studies have 
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shown that raloxifene is probably transported by Pgp [11, 12] while the corresponding 
glucuronides utilize the MRPs and organic anion transporter(s) (OAT) for their transport [12]. 
The type of MRP transporter responsible for the transport of raloxifene glucuronides has not 
been identified yet. 
The quite large inter- and intra-individual variability of raloxifene clearance, volume of 
distribution and thus its pharmacokinetics and/or pharmacodynamics, have been 
communicated [9] and we believe it could be at least partially connected to the genetic 
polymorphisms of efflux transporters that are responsible for excretion of raloxifene and its 
metabolites. 
It is well known that genetic polymorphisms present in various drug transporter genes may 
significantly affect the pharmacokinetics and pharmacodynamics of certain drugs. There are 
some quite common polymorphisms as for example c.3435C>T in ABCB1 gene and 
c.3972C>T in ABCC2 gene. The ABCB1 c.3435C>T polymorphism is expected to affect the 
expression level and function of Pgp [13] but its role in drug pharmacokinetics remains 
controversial [2]. Nevertheless, it has been published that ABCB1 c.3435C>T polymorphism 
influences the pharmacokinetics of paclitaxel [14], cyclosporine [15], phenobarbital [16], 
nelfinavir [17] and some other drugs. ABCC2 c.3972C>T is a silent single nucleotide 
polymorphism (SNP) without any effect on amino acid translation thus the influence of this 
polymorphism on pharmacokinetics is possibly mediated through a linkage disequilibrium 
with C-24T [18] or with other SNPs in ABCC2 gene that form different ABCC2 haplotypes 
[19]. Our hypothesis was that raloxifene and / or its glucuronides might be substrates for ABC 
transporters, from which we selected the ones that were most frequently associated with 
significant impact on pharmacokinetics of various other drugs, namely, Pgp, MRP1, MRP2, 
MRP3 and BCRP.  
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The aim of our study was to identify the excretory transporter(s) involved in the efflux of 
raloxifene and its three glucuronides by different in vitro assay systems and by a small in vivo 
study with a special emphasis on the involvement of Pgp, MRP1, MRP2, MRP3 and BCRP. 
In addition, the influence of Pgp and MRP2 genetic polymorphisms on both pharmacokinetics 
and pharmacodynamics of raloxifene in postmenopausal osteoporotic women was determined.  
 
1. Materials and methods 
2.1. Materials 
Raloxifene hydrochloride, fumitremorgin C (Fum C), MK571, verapamil (Ver), haloperidol, 
fluorescein (FLU), dimethylsulfoxide (DMSO), estradiol-17β-glucuronide (E17βG), formic 
acid (FA) were from Sigma-Aldrich Chemie (Deisenhofen, Germany). Raloxifene metabolites 
raloxifene-6-β-glucuronide (M1), raloxifene-4'-β-glucuronide (M2) and raloxifene-6,4'- 
diglucuronide (M3) were synthesized by incubating raloxifene with Streptomyces sp. ATCC 
55043 [20] followed by semipreparative chromatographic purification and lyophilisation. The 
details of the synthesis and purification are described elsewhere [21]. Purity was checked by 
HPLC and LC-MS/MS. Stock solutions of raloxifene, M1, M2 and M3 were prepared in 
DMSO. BD Gentest 
TM
 Pre-coated parallel artificial membrane permeability assays (PAMPA) 
Plate System was from BD Biosciences (Bedford, USA). PREDEASY
TM
 ATPase Kit was 
from SOLVO Biotechnology (Szeged, Hungary). 
3
H-estradiol-17β-glucuronide (3H-E17βG) 
and taurocholic acid (
3
H-TCA) were obtained from PerkinElmer Life Sciences (Boston, MA). 
Caco-2 cells were from American Tissue Culture Collection (ATCC) HTB.37, lot 2463681.  
 
2.2. Permeation experiments across an artificial lipid membrane (PAMPA) 
BD Gentest
TM
 Pre-coated PAMPA Plate system was used for the passive permeability 
determination of raloxifene, M1, M2 and M3. Stock solutions of the compounds were 
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prepared in DMSO.  A donor solution of 20 µM of each compound in 50 mM KH2PO4 with 
10% methanol was prepared. In each incubation, FLU (10 µM) was used as integrity marker 
of the membrane. The pH-values of the buffer solutions were adjusted to 6.5 for donor 
solution and 7.4 for acceptor solution. After incubation of PAMPA plate at room temperature 
for 5 hours, the samples for LC-MS/MS analysis were diluted four times with water 
containing 0.5 mg/L haloperidol as an internal standard and analyzed for determination of 
raloxifene, M1, M2 and M3. For determination of FLU, a fluorescence detector Tecan 
GENious (λex = 485 nm, λem = 535 nm) was used. 100 µL of a sample was diluted with 100 
µL of 0.025 M NaOH before the measurement of FLU. The data were evaluated and the 
apparent permeabilities (Papp) for raloxifene, M1, M2 and M3 were calculated by Eq. (1) and 
Eq. (2). 
 
tVVA
CtC
P
AD
mequilibriuA
app
)/1/1(
/)(1ln


                                                                                          Eq. (1) 
 
 
)(
)()(
AD
AADD
mequilibriu
VV
VtCVtC
C


                                                                                  Eq. (2) 
In this equations CD(t) and CA(t) mean compound concentration in donor and acceptor wells 
at time t, respectively. VD is donor well volume (0.3 mL) and VA is acceptor well volume (0.2 
mL), A is filter area (0.3 cm
2
) and t is incubation time (in seconds). 
 
2.3. Transport studies with Caco-2 cells 
Caco-2 cells were grown on Snapwell Costar culture inserts with a polycarbonate membrane 
(diameter 12 mm and pore size 0.4 µm). 100,000 cells/filter membrane were used for seeding 
and the medium was changed every two days. At day 15, transepithelial electrical resistance 
(TEER) was measured for each filter with Caco-2 cell monolayers. If the TEER values were 
in the range of 450–750 Ωcm2, the Caco-2 cell monolayers were used for the subsequent 
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testing of permeability at day 21. The Caco-2 cells grown on Snapwell Costar culture inserts 
were carefully rinsed with Ringer buffer and then placed between two compartments of 
EasyMount side-by-side diffusion chambers (Physiologic Instruments, SanDiego, USA). 
2.5 mL of bathing solution (Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% of fetal bovine serum) on each side of the Caco-2 cell monolayer was maintained at 
37°C and continuously oxygenated and circulated by bubbling with carbogen (95% O2, 5% 
CO2). After 25 min of preincubation, 0.5 mL of the concentrated solution containing 
raloxifene was added to the apical side (if studying apical-to-basolateral (A–B) transport) or 
to the basolateral side (if studying basolateral-to-apical (B–A) transport). The concentrated 
solution contained 30 µmol/L raloxifene. When evaluating the impact of different ABC efflux 
transporters on raloxifene transport through Caco-2 cell monolayers, specific inhibitors were 
added at appropriate concentration to the apical side (Pgp inhibitor verapamil, 100 µmol/L; 
MRP inhibitor MK571, 25 µmol/L; BCRP inhibitor Fum C, 10 µmol/L). 100 µL of samples 
were withdrawn from the acceptor side every 20 min up to 100 min, and replaced each time 
by fresh DMEM containing all necessary ingredients at appropriate concentrations. Caco-2 
incubation samples (100 L) were treated by three volumes of methanol containing 0.5 mg/L 
of haloperidol as an internal standard and were left on -20°C for 48h, centrifuged at 1300  g 
for 2 hours and the supernatants were subjected for LC-MS/MS analysis. Only those Caco-2 
cell monolayers whose TEER values remained constant during the whole experiment were 
used.  
The transepithelial potential difference (PD) and short circuit current (Isc) were measured as 
shown in Berginc et al. [22]. By monitoring PD, Isc and TEER every 20 min during the 
experiments, the viability and integrity of Caco-2 cell monolayer were checked. 
 
Data analysis 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
The apparent permeability coefficient (Papp) was calculated according to Eq. (3). 
ACdt
VdC
Papp



0
                                                                                                               Eq. (3) 
where dc/dt is the change in concentration of the examined substance in the acceptor 
compartment per unit time under steady state conditions, V is the volume of the acceptor 
compartment, A the exposed surface area (1.13 cm
2
) and c0 the initial concentration of the 
examined substance in the donor solution. 
 
When testing the influence of inhibitors of the tested transporters for involvement in 
raloxifene transport, the efflux ratio (ER) was calculated according to Eq. (4).  
)(
)(
BAP
ABP
ER
app
app


                                                                                                               Eq. (4) 
where Papp(B - A) and Papp(A - B) represent the apparent permeability of raloxifene 
determined in B - A and A - B directions, respectively. Results in tables are presented as 
means ± SD of at least three measurements. Data were evaluated statistically using PASW 
18.0 for Windows. F-test for testing the equality of variances and, two tailed t-test (α = 0.05) 
were used.  
 
2.4. Membrane-based assays for ABC transporters 
2.4.1.  ATPase assay 
ATPase activities of activated and non-activated transporters (Pgp, MRP1, MRP2, MRP3, 
BCRP) was measured by using PREDEASY 
TM 
ATPase Kits according to the manufacturer's 
instructions. In brief, membrane vesicles were diluted with assay mix (50 mM Mops-Tris, 50 
mM KCl, 5 mM Na-azide, 2 mM DTT, 0.1 mM EGTA-Tris, 1 mM ouabain in distilled water 
at pH 7.0) to 0.1 µg/µL and a 40 µL aliquote of this dilution was preincubated with one µL of 
tested compound diluted in DMSO with or without sodium orthovanadate (1.2 mM) for 10 
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minutes at 37 °C. Concentration range for tested compounds were 0.39 – 50 µM, 0.32 – 41.4 
µM, 0.25 – 31.4 µM and 0.06 – 8 µM for raloxifene, M1, M2 and M3, respectively. After 
preincubation, the reaction was started by addition of 10 µL of Mg-ATP (0.2 M). The ATPase 
reaction was stopped after 10 min at 37°C and the concentration of liberated inorganic 
phosphate was determined colorimetrically by measuring the absorbance at 600 nm. 
Activation and inhibition experiments were prepared by ATPase assay. For the activation and 
inhibition experiment in addition to listed compounds 2 mM glutathione was used for MRP1, 
MRP2 and MRP3. For the inhibition experiment, ATPase assays were performed in the 
presence of activator substance 40 µM verapamil for Pgp, 10 mM N-ethylmaleimide 
glutathione for MRP1, 100 µM sulfasalazine for MRP2, 50 µM benzbromarone for MRP3 
and 10 µM sulfasalazine for BCRP. Results were calculated using MS Excel 2007. 
 
2.4.2. Membrane vesicular transport studies 
BSEP [23] and MRP2 [24] were expressed in Sf9 and Sf21 cells, respectively using standard 
methodology. Vesicles were isolated from carrier expressing insect cells as described by 
Gerloff et al. [25]. They were resuspended in 50 mM sucrose, 100 mM KNO3, 5 mM 
Mg(NO3)2, 10 mM HEPES/Tris pH 7.4 and stored in liquid nitrogen until use. Uptake 
experiment of 2.5 µM taurocholate into BSEP expressing vesicles and 10 µM E17βG into 
MRP2 expressing vesicles in the presence and absence of 6.25 mM ATP was determined with 
the rapid-filtration methodology. The vesicular transport was terminated at 0 minutes and 10 
minutes and the uptake was calculated first by subtracting the 0 min time point and second by 
subtracting the uptake in the absence of ATP. Raloxifene, M1, M2 and M3 were tested as 
inhibitors of E17βG uptake by MRP2 or BSEP at concentrations of 10, 10, 10, 4 µM, 
respectively. 
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2.5. Liquid chromatography-tandem mass spectrometry conditions  
Caco-2 and PAMPA samples were subjected to LC-MS/MS analysis. The Agilent 1290 
Infinity ultra-high pressure liquid chromatographic system (Agilent Techologies, Santa Clara, 
USA) was coupled to a 6460 Triple Quad Mass Spectrometer (Agilent Techologies, Santa 
Clara, USA). The chromatographic separation was performed on a Kinetex 50 × 2.1 mm 
column with 2.6 µm particles with an In-Line filter KrudKatcher Ultra HPLC 0.5 µm and a 
guard column C18 (2) 4 × 2 mm (Phenomenex, Torrance, USA). The column temperature 
was 50°C. The mobile phase consisted of 0.1% FA in water (mobile phase A) and 98% 
acetonitrile (mobile phase B). The flow rate was set at 0.65 mL/min and the separation 
required a gradient elution. The elution started with 10% of mobile phase B for 0.25 min, and 
then the elution continued with the following gradient: 10%-20%-30%-50%-50%-10% of 
mobile phase B in 0.25-0.50-1.00-1.25-1.70-1.75 min, respectively. The chromatographic 
system was coupled to 6460 Triple Quad Mass Spectrometer with JetStream
TM
 electrospray 
ionization (Agilent Techologies, Santa Clara, USA) operated in positive mode. Instrument 
parameters were set as follows: drying gas temperature 275°C, drying gas flow 5 L/min, 
nebulizer 45 PSI, sheath gas temperature 320°C, sheath gas flow 11 L/min, capillary entrance 
voltage 4000 V, nozzle voltage 1000V, delta EMV 200V. Both quadrupoles Q1 and Q3 were 
set at wide mass resolution and dwell time was 50 ms. Instrument control, data acquisition 
and quantification were performed by MassHunter Workstation software B.03.01 (Agilent 
Technologies, Torrance, USA). The MRM m/z transitions and collision energy characteristics 
for optimal quantification were 474 → 112, 32 eV for raloxifene, 650 → 474, 28 eV for M1 
and M2, 826 → 474, 40 eV for M3 and 376 → 165, 32 eV for haloperidol (internal standard). 
 
2.6. Clinical study 
2.6.1. Study design 
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A total of 57 postmenopausal female patients with osteoporosis were enrolled in the study. 
The inclusion criteria were: osteoporosis (low BMD, T score <-2.5 SD or presence of 
verterbral, femoral or radius fracture), 5 years or more of menopause, and age of less than 70. 
The exclusion criteria were: prior history of venous thromboembolic or malignant disease, 
serious liver or kidney deficiency, smoking, osteoporosis treatment, lipid lowering or 
glucocorticoid treatment, estrogen hormone replacement therapy within 6 months prior to the 
enrolment. The research was carried out according to the principles of the Declaration of 
Helsinki and was in compliance with local regulatory requirements. A written informed 
consent was obtained from each individual and the study protocol was approved by the 
Slovenian National Medical Ethics Committee. The patients were treated for 12 months with 
60 mg raloxifene per day and were followed in the University Medical Centre (Maribor, 
Slovenia). Four patients resigned from the study due to not following the study protocol. 
At baseline, blood was drawn for the measurements of bone turnover markers and DNA 
extraction. All investigations were carried out at 8 a.m. after an overnight fast. After the first 
visit, the participants started with raloxifene 60 mg, cholecalciferol 400 I.U. and calcium 
carbonate 1000 mg daily. Patients did not get any dietary advice. Compliance was checked 
orally by a physician at 3, 6 and 12 months of the therapy. After 12 months, blood was drawn 
for the measurements of bone turnover markers (serum bone-specific alkaline phosphatase 
(BALP), serum osteocalcin (OC), serum C-terminal telopeptide fragments of type I collagen 
(CTX) and concentrations of raloxifene, M1, M2 and M3. After centrifugation, the serum 
samples were stored at -86°C until analysis. The BMD of total hip (BMD-HIP), femoral neck 
(BMD-FN) and lumbar spine L1-L4 (BMD-LS,) and three quantitative ultrasound parameters, 
heel speed of sound (SOS), broadband ultrasound attenuation (BUA) and quantitative 
ultrasound index (QUI) were measured at baseline and after 12 months of raloxifene therapy. 
The statistical power of the study was calculated to be adequate to detect at least 50 % 
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difference in raloxifene species concentrations among the genotype groups with frequencies 
of at least 23%, assuming 50% RSD [9]. Additionally,  the statistical power was calculated to 
be sufficient to detect at least 2% difference in delta BMD after 12 months of treatment in 
different groups with polymorphic genotype frequencies of at least 14% (assuming 50% RSD, 
=0.05, 1-=0.80). 
 
2.6.2. Determination of raloxifene and its metabolites in serum 
The method used for determination of M1, M2 and raloxifene had been developed and 
validated previously in our laboratory and is described in full detail elsewhere [26]. 
Additionally, the metabolite M3 was monitored. In the present study, the selected reaction 
monitoring mode (SRM) set at 826→474 (m/z transition) was used for the quantification of 
M3 using the haloperidol as an internal standard. The limit of detection for M3 was 0.039 nM, 
the limit of quantification was 0.88 nM and the linear range for M3 was from 0.88 nM to 
4800 nM. The intra- and inter- day precisions were 2.4 and 1.3%, respectively. 
TR (total raloxifene) was calculated as a summation of molar concentrations of raloxifene, 
M1, M2 and M3. 
 
2.6.3. Determination of pharmacodynamic parameters 
BMD-HIP, BMD-FN and BMD-LS were determined by dual energy X-ray absorptiometry 
(DXA) with a Hologic QDR-2000+ densitometer (Hologic Inc. Waltham, USA). 
Quantitative ultrasound (QUS) measurements of the calcaneus were performed on the left 
heel of all study participants, with the subject in the sitting position, using a Sahara apparatus 
(Hologic Inc. Waltham, USA). Three QUS parameters of calcaneus were measured: SOS, 
BUA and QUI. An average of two measurements was calculated. 
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BALP was assessed by IRMA (Tandem
®
-R Ostase
®
; Beckman Coulter). OC was measured 
using a two-site immunoluminometric Elecsys N-MID Osteocalcin assay (Roche Diagnostics, 
Mannheim, Germany) [27]. CTX was measured using a two-site immunoluminometric 
Elecsys Beta CrossLaps assay (Roche Diagnostics, Mannheim Germany) [27]. 
  
2.6.4. ABCB1 and ABCC2 genotyping  
Genomic DNA was isolated from peripheral blood leukocytes by using a FlexiGene DNA kit 
(Qiagen, Hilden, Germany). Two SNPs in two different genes c.3435C>T (rs1045642) in the 
ABCB1 gene and c.3972C>T (rs3740066) in the ABCC2 gene were genotyped using validated 
TaqMan Assays (C__7586657_20 and C__11214910_20) from Applied Biosystems in an 
ABI Prism 7000 sequence detection system, under the conditions recommended by the 
manufacturer (Applied Biosystems, Foster City, CA, USA). To validate our results, a random 
selection of 10% of the samples was re-genotyped for each SNP, and the results were found to 
be reproducible with no discrepancies noted. 
 
2.6.5. Statistical analysis 
The Shapiro-Wilk goodness-of-fit test was used to determine the normality of data 
distribution and the Levene’s test was used to test the homogeneity of variances prior to the 
ANOVA and the t-test. A square root transformation was applied to the concentrations of 
raloxifene, M1, M2, M3 and TR in order to obtain a normal data distribution. The Bonferroni 
post hoc test was used to compare the means from genotype groups for each polymorphism. 
The calculation of percentage change of the pharmacodynamic parameters (PD) during 
treatment was calculated according to the Eq. (5).  
%100)(
0
120




parameterPD
parameterPDparameterPD
parameterPD
monthstt
                           Eq. (5) 
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To test the influence of genotype on raloxifene species concentration level and on percentage 
change of pharmacodynamic parameters during treatment, the ANOVA was applied. The 
Hardy-Weinberg equilibrium was tested for each polymorphism using the χ2 test. The 
significance criterion (α) was set at p < 0.05. Data analyses were performed by PASW 18.0 
software (IBM company, Illinois, Chicago, USA). 
 
3. Results 
3.1.   Passive permeability measurements  
The passive part of raloxifene species permeability was assessed with a PAMPA model. The 
rank order of the compound permeability through the PAMPA membrane shows that 
raloxifene has the highest passive permeability, followed by raloxifene monoglucuronides and 
M3, with the lowest passive permeability (Table 1).  
 
3.2. Transcellular transport assay 
Caco-2 cell monolayers were used for the identification of transporters involved in raloxifene 
transport and for the determination of absorptive raloxifene permeability. The results indicate 
a decrease in raloxifene efflux ratio, when verapamil (Pgp inhibitor) [22] was applied to the 
apical side. Fum C (BCRP inhibitor) [28] and MK571 (MRP inhibitor) [29] did not cause any 
significant changes in the efflux ratio (Table 2). Contrary to the previously published results 
by Jeong et al. [12], we did not observe any raloxifene glucuronides nor sulfates formation on 
either donor or acceptor sides.  
 
3.3. ATPase assay 
The results of activation and inhibition experiments on transporter ATPases are presented in 
Tables 3 A and 3 B. It has been previously documented that the modulation of ABC 
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transporter-specific ATP hydrolysis by a given test compound is a clear sign of its interaction 
with the protein [30]. The results of activation and inhibition tests for raloxifene, M1, M2 and 
M3 are shown in Tables 3 A and 3 B. In the activation experiment raloxifene and M3 
activated the utilization of ATP by Pgp to promote the transport of these two raloxifene 
species across the membrane. The utilization of ATP was increased also in the case of M3 
when it was incubated with MRP1 membranes. Raloxifene, M1 and M2 increased the 
utilization of ATP by MRP3. When the tested raloxifene species were incubated with BCRP 
vesicles there was no change in ATP hydrolysis. In the inhibition experiment an inhibition of 
activated ATPase activity was observed in all cases except when incubating M1 with MRP2 
membranes. 
 
3.4. Vesicular transport (BSEP, MRP2) 
Fig. 1 shows the uptake of E17βG as a typical substrate for MRP2 in the absence and 
presence of raloxifene species as inhibitors. It was observed that M2 and M3, but not M1 and 
raloxifene significantly inhibited the uptake of E17βG. On the contrary, no inhibition of 
taurocholate as a typical BSEP substrate was observed in incubation of raloxifene species 
with BSEP vesicles (data not shown). 
 
3.5. Patient's genotype frequencies 
Patient's genotype frequencies for the ABCB1 c.3435C>T and ABCC2 c.3972C>T 
polymorphisms are shown in Table 4. The tested polymorphisms were chosen on the basis of 
variant allele frequencies that were 46.0%, 32.1% and 9.5% for ABCB1 c.3435C>T [31],  
ABCC2 c.3972C>T [18] and ABCG2 c. 421C>A [32], respectively. Due to a relatively small 
number of study participants and low allelic frequency the genotyping for ABCG2 c. 421C>A 
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was not performed. All genotype frequencies were found to be in Hardy-Weinberg 
equilibrium (p>0.05). 
 
3.6. Effect of ABCB1 c.3435C>T and ABCC2 c.3972C>T on plasma concentration of 
raloxifene species 
The effect of ABCB1 c.3435C>T and ABCC2 c.3972C>T polymorphisms on plasma 
concentration of raloxifene, M1, M2 and M3 was not found to be significant. The ABCB1 
3435CT and TT variants exhibited a trend toward increased serum concentrations of all tested 
raloxifene species over homozygous wild-type, but did not reach statistical significance 
(Table 5). 
 
3.7. Effects of ABCB1 c.3435C>T and ABCC2 c.3972C>T on pharmacodynamic 
parameters 
A significant difference in percent change in BMD-HIP after 1 year of raloxifene treatment 
was observed in subjects according to the ABCB1 c.3435C>T polymorphism. Patients 
homozygous for the T allele compared with the heterozygote and the wild-type experienced a 
higher increase in BMD-HIP after 1 year (Table 6). On the other hand, the changes in BMD-
LS and BMD-FN and changes in bone turnover markers were not significant. 
 
4. Discussion 
The main goal of our study was to determine which excretory transporters may play a 
significant role in the disposition of raloxifene and may also be involved in the observed 
variability in raloxifene exposure and therapeutic effect. Complex in vitro and in vivo 
approaches have been utilized to comprehensively describe the excretory transport of 
raloxifene and its conjugates. We have shown a strong in vitro evidence of raloxifene species 
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interaction with Pgp and MRP transporters which encouraged us to perform an in vivo study 
to evaluate the influence of genetic polymorphisms of these two transporters on both 
raloxifene pharmacokinetics and pharmacodynamics. 
 Although raloxifene conjugates do not bind with estrogen receptors with affinity high enough 
to evoke a pharmacological response they are considered as carriers of active raloxifene [9, 
10]. Their blood serum concentration is more than hundred times higher than raloxifene serum 
concentration (Table 5) and they can be cleaved back to parent raloxifene in many tissues and 
organs [7, 10]. Therefore, in order to elucidate the complex raloxifene disposition it is vital to 
understand raloxifene glucuronide membrane transport and its effect on both raloxifene 
pharmacokinetics and pharmacodynamics. 
First, PAMPA was used to predict the passive transcellular permeability of raloxifene, M1, 
M2 and M3. Secondly, a cell based transport assay for the possible involvement of Pgp, MRP 
and BCRP was performed on Caco2 cells. Thirdly, two types of membrane-based assays were 
performed: ATPase assay for Pgp, MRP1, MRP2, MRP3 and BCRP and vesicular transport 
assay for BSEP and MRP2. Finally, an in vivo study on postmenopausal women with 
osteoporosis was undertaken to test the clinical significance of genetic polymorphisms in 
genes coding for Pgp and MRP2, which were found to interact either with raloxifene or its 
glucuronides.  
As expected, the PAMPA experiments showed significant differences in passive permeability 
coefficients of raloxifene species. Raloxifene permeability was the highest, followed by its 
more hydrophilic metabolites M1, M2 and M3. From these results it is clear that raloxifene 
conjugates require an active or facilitated transport to efficiently cross the biological 
membranes. The Caco2 cell line was used for further permeability studies to reveal the 
possible participation of membrane transporters during the raloxifene absorption phase. The 
measured raloxifene Caco2 permeability was higher than reported permeability of estradiol 
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and lower than reported permeability of tamoxifen (7.9 ± 1.1 vs 1.2 ± 0.8 vs 47.4 ± 21.0 [*10-6 
cm/s] , respectively) [33, 34]. The obtained efflux ratio for raloxifene (ER) of 11.7 (Table 2) 
showed that raloxifene is actively excreted from the Caco2 cells, while a significant drop of 
ER to 6.2 observed in the presence of verapamil (a Pgp inhibitor) suggests that raloxifene 
excretion from Caco2 cells is largely mediated by Pgp, which is in accordance with findings 
of Jeong et al. [12] and Chang et al. [11]. On the other hand, no significant changes in efflux 
ratio were detected with either the MRP or BCRP inhibitors. Caco2 transport experiments 
with raloxifene conjugates (M1, M2, M3) could not be performed due to the limited amounts 
of synthesized standards. To investigate the interactions between raloxifene species and 
individual transporters, the ATP-ase membrane assays and inside-out membrane vesicles were 
performed, which consumed lesser amounts of metabolite standards. The modulation of ABC 
transporter-specific ATP hydrolysis by a test compound was taken as a sign of its interaction 
with the studied transporter. ATP-ase activation suggested the presence of an actively 
transported compound, while an inhibition of activated transporter (in a separate experiment) 
indicated a low transport rate or a direct inhibition of the transporter. The results from 
membrane preparations were complex and rather difficult to interpret. However, it is safe to 
assume the following conclusions: raloxifene is a Pgp substrate because of the positive results 
on Caco2 with verapamil and weak activation and strong inhibition of Pgp ATP-ase. 
Furthermore, M2 and M3 could be MRP2 substrates or inhibitors because of the observed 
inhibition and activation of MRP2 ATP-ase and significant inhibition of E17βG vesicular 
uptake. Moreover, there were significant activation and/or inhibition interactions detected 
between raloxifene species and MRP1 and MRP3 transporters. Therefore it was deemed 
reasonable to expect a significant influence of the studied transporters on raloxifene 
disposition. To determine the in vivo effects of efflux transporters’ genetic polymorphisms, a 
clinical study on postmenopausal women with osteoporosis was undertaken. Serum 
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concentrations of raloxifene, M1, M2 and M3 were determined using a validated LC-MS/MS 
method. Patients were genotyped for ABCB1 c.3435C>T and ABCC2 c.3972C>T and it was 
found that none of the tested polymorphisms significantly influenced the serum 
concentrations of raloxifene species. However, in the case of ABCB1 c.3435C>T a trend 
towards higher concentrations of raloxifene species in patients with at least one polymorphic 
allele was observed but due to an unexpectedly high interindividual variability it was not 
significant. The observed polymorphism effect of higher raloxifene species concentrations 
could be explained by a lower Pgp expression levels in both liver and intestine in carriers of 
polymorphic alleles leading to a decreased raloxifene species excretion and consequently to 
their higher serum levels. This explanation is in accordance with the previous results obtained 
by Hoffmeyer et al. [13] where it was postulated that individuals homozygous for this 
polymorphism had significantly lower MDR1 expression levels and dysfunction of MDR1. 
Furthermore, raloxifene is extensively conjugated in both enterocytes and hepatocytes to its 
metabolites. Consequently, a decreased Pgp activity would also increase raloxifene exposure 
to the UGTs, therefore this may explain why the concentrations of raloxifene metabolites in 
serum tended to be higher in patients with polymorphic MDR1. 
Besides the pharmacokinetic changes, we also evaluated the percent change in 
pharmacodynamic parameters after 1 year of raloxifene treatment. It was discovered that 
ABCB1 c.3435C>T polymorphism significantly influenced the percent change of BMD-HIP 
after 12 months of raloxifene treatment.  Based on the results (Table 6), individuals 
homozygous for the c.3435T variant experienced a significantly higher increase in BMD-HIP 
than the wild-type homozygotes. This is in accordance with the observed trend of higher 
concentrations of raloxifene species in patients with ABCB1 c.3435TT genotype.  To further 
explore the connection between raloxifene efficacy and safety profile with the presence of the 
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relatively frequent c. ABCB1 3435C>T polymorphism, it would be advisable to conduct a 
larger prospective cohort study. 
In conclusion, we discovered which transporters are most likely involved in the excretion of 
raloxifene species into bile, which is a very important step in the enterohepatic recirculation 
of raloxifene and therefore an important determinant for the overall raloxifene exposure. The 
presented data implicate that at least a part of the observed variability could be explained by 
the genetic influence of ABCB1 c.3435C>T polymorphism. In this study, the synergistic use 
of in vitro models combined with a small in vivo study has proven to be successful in 
identification of relevant transporters and confirmation of their in vivo effects. The presented 
multidisciplinary approach of translational research yielded an insight into complex 
mechanisms of raloxifene disposition and the gained knowledge may thus insure a safer and 
more effective treatment strategy in the clinical setting. 
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Legends for figures 
Fig. 1: Inhibitory effects of raloxifene, raloxifene-6-β-glucuronide (M1), raloxifene-4'-β-
glucuronide (M2), raloxifene-6,4'-diglucuronide (M3) on active uptake of estradiol-17β-
glucuronide (E17βG) into MRP2 expressing membrane vesicles. Each column represents the 
mean (SE) (n=4) and (*) indicates a significant difference from the control (p < 0.05). 
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Abstract 
Raloxifene exhibits quite a large and unexplained interindividual variability in its 
pharmacokinetics and pharmacodynamics. The aim of our study was to identify transporters 
involved in the efflux of raloxifene and its glucuronide metabolites by various in vitro models 
and by an in vivo study to explore the possible involvement of Pgp, MRP1, MRP2, MRP3, 
and BCRP in the observed high interindividual variability. Experiments with PAMPA 
(Parallel Artificial Membrane Permeability Assay) showed the highest passive permeability 
for raloxifene, followed by raloxifene-6-β-glucuronide (M1), raloxifene-4'-β-glucuronide 
(M2) and raloxifene-6,4'-diglucuronide (M3). Caco-2 cell monolayer experiments indicated 
an interaction of raloxifene with Pgp. The ATPase assay confirmed the raloxifene interaction 
with Pgp, and also indicated interactions of all raloxifene species with MRP1, MRP2, MRP3 
and BCRP, except for M1 which did not show any interactions with MRP2. Furthermore, the 
vesicular experiments confirmed the interaction of M2 and M3 with MRP2. Although the in 
vivo study on osteoporotic postmenopausal women on raloxifene could not confirm a 
significant influence of ABCB1 and ABCC2 genetic polymorphisms on its pharmacokinetics, 
a clear trend towards higher total raloxifene concentrations was observed in carriers of at least 
one ABCB1 c.3435T allele. Moreover, the same polymorphism effect was also observed as a 
significant increase in total hip bone mineral density after 1 year of treatment. In conclusion, 
the results of our study support the involvement of efflux transporters in disposition of 
raloxifene and its metabolites and may partially explain the observed raloxifene variability by 
the influence of the ABCB1 c.3435C>T polymorphism.  
 
Keywords: raloxifene, efflux transporters, genetic polymorphisms, pharmacokinetics, 
pharmacodynamics, translation 
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Running head and abbreviations 
Running head: Efflux transporters and raloxifene  
Abbreviations: ABC transporters, ATP-binding cassette transporters; ABCB1, ATP-binding 
cassette transporter B1 gene (Pgp); ABCC2, ATP-binding cassette transporter C2 gene 
(MRP2);  BALP, serum bone-specific alkaline phosphatase; BCRP, breast cancer resistance 
protein; BMD, bone mineral density; BMD-FN, bone mineral density of femoral neck; BMD-
HIP, bone mineral density of total hip; BMD-LS, bone mineral density of lumbar spine L1-
L4; BSEP, bile salt export pump; BUA, broadband ultrasound attenuation; CTX, serum C-
terminal telopeptide fragments of type I collagen; DMSO, dimethylsulfoxide; E17βG , 
estradiol-17β-glucuronide; FA, formic acid; FLU, fluorescein; FumC, fumitremorgin C; LC-
MS/MS, liquid chromatography - tandem mass spectrometry; M1, raloxifene-6-β-
glucuronide; M2, raloxifene-4'-β-glucuronide; M3, raloxifene-6,4'-diglucuronide; MRP, 
multidrug resistance-associated protein; OC, osteocalcin; PAMPA, parallel artificial 
membrane permeability assay; Pgp, P-glycoprotein; QUI, quantitative ultrasound index; SNP, 
single nucleotide polymorphism; SOS, heel speed of sound; UGTs, UDP-
glucuronosyltransferases.
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Introduction 
ATP-binding cassette (ABC) transporters work in concert to control the bioavailability of 
drugs and are thus important determinants of drug-drug interactions, drug efficacy and 
toxicity. P-glycoprotein (Pgp), multidrug resistance-associated proteins (MRPs), breast cancer 
resistance protein (BCRP) and bile salt export pump (BSEP) are efflux transporters, which 
have been well characterized for their ability to transport xenobiotics and endobiotics [1, 2].  
Raloxifene, a selective estrogen receptor modulator, is approved worldwide for the prevention 
and treatment of postmenopausal osteoporosis and for the prevention of breast cancer in 
postmenopausal women. Raloxifene therapy suppresses the bone turnover to normal 
premenopausal range, thereby increasing bone mineral density (BMD) in the spine, hip and 
total body [3, 4], reducing the risk for vertebral fractures [5] but not changing non-vertebral 
fracture risk [6]. After peroral application, raloxifene undergoes a rapid absorption, an 
extensive first-pass metabolism and an entero-hepatic cycling. According to the estimations, 
the fraction of raloxifene absorbed is high, 60 %, but only 2% reaches the systemic circulation 
in unconjugated form due to the high metabolic turnover during absorption [7]. The rest 
represents raloxifene conjugated by UDP-glucuronosyltransferases (UGTs) to raloxifene-4'-β-
glucuronide (M2), raloxifene-6-β-glucuronide (M1) [7, 8] and raloxifene-6,4'-diglucuronide 
(M3) [7, 9]. Although the glucuronides show little affinity for the estrogen receptors and for 
bone tissue, they are important because they can be readily reconverted back into active 
raloxifene in various organs by β-glucuronidases residing in the liver, lung, spleen, kidney, 
bone and uterus [10]. Raloxifene and its metabolites are primarily excreted in feces and less 
than 0.2% and 6% of raloxifene and its metabolites, respectively, are recovered in urine [7]. 
This fact, coupled with the observation of a major entero-hepatic cycling, suggests an 
important role of efflux transporters located in the canalicular membrane of hepatocytes 
and/or in the brush border membrane of intestinal epithelial cells. Previous studies have 
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shown that raloxifene is probably transported by Pgp [11, 12] while the corresponding 
glucuronides utilize the MRPs and organic anion transporter(s) (OAT) for their transport [12]. 
The type of MRP transporter responsible for the transport of raloxifene glucuronides has not 
been identified yet. 
The quite large inter- and intra-individual variability of raloxifene clearance, volume of 
distribution and thus its pharmacokinetics and/or pharmacodynamics, have been 
communicated [9] and we believe it could be at least partially connected to the genetic 
polymorphisms of efflux transporters that are responsible for excretion of raloxifene and its 
metabolites. 
It is well known that genetic polymorphisms present in various drug transporter genes may 
significantly affect the pharmacokinetics and pharmacodynamics of certain drugs. There are 
some quite common polymorphisms as for example c.3435C>T in ABCB1 gene and 
c.3972C>T in ABCC2 gene. The ABCB1 c.3435C>T polymorphism is expected to affect the 
expression level and function of Pgp [13] but its role in drug pharmacokinetics remains 
controversial [2]. Nevertheless, it has been published that ABCB1 c.3435C>T polymorphism 
influences the pharmacokinetics of paclitaxel [14], cyclosporine [15], phenobarbital [16], 
nelfinavir [17] and some other drugs. ABCC2 c.3972C>T is a silent single nucleotide 
polymorphism (SNP) without any effect on amino acid translation thus the influence of this 
polymorphism on pharmacokinetics is possibly mediated through a linkage disequilibrium 
with C-24T [18] or with other SNPs in ABCC2 gene that form different ABCC2 haplotypes 
[19]. Our hypothesis was that raloxifene and / or its glucuronides might be substrates for ABC 
transporters, from which we selected the ones that were most frequently associated with 
significant impact on pharmacokinetics of various other drugs, namely, Pgp, MRP1, MRP2, 
MRP3 and BCRP.  
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The aim of our study was to identify the excretory transporter(s) involved in the efflux of 
raloxifene and its three glucuronides by different in vitro assay systems and by a small in vivo 
study with a special emphasis on the involvement of Pgp, MRP1, MRP2, MRP3 and BCRP. 
In addition, the influence of Pgp and MRP2 genetic polymorphisms on both pharmacokinetics 
and pharmacodynamics of raloxifene in postmenopausal osteoporotic women was determined.  
 
1. Materials and methods 
2.1. Materials 
Raloxifene hydrochloride, fumitremorgin C (Fum C), MK571, verapamil (Ver), haloperidol, 
fluorescein (FLU), dimethylsulfoxide (DMSO), estradiol-17β-glucuronide (E17βG), formic 
acid (FA) were from Sigma-Aldrich Chemie (Deisenhofen, Germany). Raloxifene metabolites 
raloxifene-6-β-glucuronide (M1), raloxifene-4'-β-glucuronide (M2) and raloxifene-6,4'- 
diglucuronide (M3) were synthesized by incubating raloxifene with Streptomyces sp. ATCC 
55043 [20] followed by semipreparative chromatographic purification and lyophilisation. The 
details of the synthesis and purification are described elsewhere [21]. Purity was checked by 
HPLC and LC-MS/MS. Stock solutions of raloxifene, M1, M2 and M3 were prepared in 
DMSO. BD Gentest 
TM
 Pre-coated parallel artificial membrane permeability assays (PAMPA) 
Plate System was from BD Biosciences (Bedford, USA). PREDEASY
TM
 ATPase Kit was 
from SOLVO Biotechnology (Szeged, Hungary). 
3
H-estradiol-17β-glucuronide (3H-E17βG) 
and taurocholic acid (
3
H-TCA) were obtained from PerkinElmer Life Sciences (Boston, MA). 
Caco-2 cells were from American Tissue Culture Collection (ATCC) HTB.37, lot 2463681.  
 
2.2. Permeation experiments across an artificial lipid membrane (PAMPA) 
BD Gentest
TM
 Pre-coated PAMPA Plate system was used for the passive permeability 
determination of raloxifene, M1, M2 and M3. Stock solutions of the compounds were 
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prepared in DMSO.  A donor solution of 20 µM of each compound in 50 mM KH2PO4 with 
10% methanol was prepared. In each incubation, FLU (10 µM) was used as integrity marker 
of the membrane. The pH-values of the buffer solutions were adjusted to 6.5 for donor 
solution and 7.4 for acceptor solution. After incubation of PAMPA plate at room temperature 
for 5 hours, the samples for LC-MS/MS analysis were diluted four times with water 
containing 0.5 mg/L haloperidol as an internal standard and analyzed for determination of 
raloxifene, M1, M2 and M3. For determination of FLU, a fluorescence detector Tecan 
GENious (λex = 485 nm, λem = 535 nm) was used. 100 µL of a sample was diluted with 100 
µL of 0.025 M NaOH before the measurement of FLU. The data were evaluated and the 
apparent permeabilities (Papp) for raloxifene, M1, M2 and M3 were calculated by Eq. (1) and 
Eq. (2). 
 
tVVA
CtC
P
AD
mequilibriuA
app
)/1/1(
/)(1ln


                                                                                          Eq. (1) 
 
 
)(
)()(
AD
AADD
mequilibriu
VV
VtCVtC
C


                                                                                  Eq. (2) 
In this equations CD(t) and CA(t) mean compound concentration in donor and acceptor wells 
at time t, respectively. VD is donor well volume (0.3 mL) and VA is acceptor well volume (0.2 
mL), A is filter area (0.3 cm
2
) and t is incubation time (in seconds). 
 
2.3. Transport studies with Caco-2 cells 
Caco-2 cells were grown on Snapwell Costar culture inserts with a polycarbonate membrane 
(diameter 12 mm and pore size 0.4 µm). 100,000 cells/filter membrane were used for seeding 
and the medium was changed every two days. At day 15, transepithelial electrical resistance 
(TEER) was measured for each filter with Caco-2 cell monolayers. If the TEER values were 
in the range of 450–750 Ωcm2, the Caco-2 cell monolayers were used for the subsequent 
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testing of permeability at day 21. The Caco-2 cells grown on Snapwell Costar culture inserts 
were carefully rinsed with Ringer buffer and then placed between two compartments of 
EasyMount side-by-side diffusion chambers (Physiologic Instruments, SanDiego, USA). 
2.5 mL of bathing solution (Dulbecco's modified Eagle's medium (DMEM) supplemented 
with 10% of fetal bovine serum) on each side of the Caco-2 cell monolayer was maintained at 
37°C and continuously oxygenated and circulated by bubbling with carbogen (95% O2, 5% 
CO2). After 25 min of preincubation, 0.5 mL of the concentrated solution containing 
raloxifene was added to the apical side (if studying apical-to-basolateral (A–B) transport) or 
to the basolateral side (if studying basolateral-to-apical (B–A) transport). The concentrated 
solution contained 30 µmol/L raloxifene. When evaluating the impact of different ABC efflux 
transporters on raloxifene transport through Caco-2 cell monolayers, specific inhibitors were 
added at appropriate concentration to the apical side (Pgp inhibitor verapamil, 100 µmol/L; 
MRP inhibitor MK571, 25 µmol/L; BCRP inhibitor Fum C, 10 µmol/L). 100 µL of samples 
were withdrawn from the acceptor side every 20 min up to 100 min, and replaced each time 
by fresh DMEM containing all necessary ingredients at appropriate concentrations. Caco-2 
incubation samples (100 L) were treated by three volumes of methanol containing 0.5 mg/L 
of haloperidol as an internal standard and were left on -20°C for 48h, centrifuged at 1300  g 
for 2 hours and the supernatants were subjected for LC-MS/MS analysis. Only those Caco-2 
cell monolayers whose TEER values remained constant during the whole experiment were 
used.  
The transepithelial potential difference (PD) and short circuit current (Isc) were measured as 
shown in Berginc et al. [22]. By monitoring PD, Isc and TEER every 20 min during the 
experiments, the viability and integrity of Caco-2 cell monolayer were checked. 
 
Data analysis 
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The apparent permeability coefficient (Papp) was calculated according to Eq. (3). 
ACdt
VdC
Papp



0
                                                                                                               Eq. (3) 
where dc/dt is the change in concentration of the examined substance in the acceptor 
compartment per unit time under steady state conditions, V is the volume of the acceptor 
compartment, A the exposed surface area (1.13 cm
2
) and c0 the initial concentration of the 
examined substance in the donor solution. 
 
When testing the influence of inhibitors of the tested transporters for involvement in 
raloxifene transport, the efflux ratio (ER) was calculated according to Eq. (4).  
)(
)(
BAP
ABP
ER
app
app


                                                                                                               Eq. (4) 
where Papp(B - A) and Papp(A - B) represent the apparent permeability of raloxifene 
determined in B - A and A - B directions, respectively. Results in tables are presented as 
means ± SD of at least three measurements. Data were evaluated statistically using PASW 
18.0 for Windows. F-test for testing the equality of variances and, two tailed t-test (α = 0.05) 
were used.  
 
2.4. Membrane-based assays for ABC transporters 
2.4.1.  ATPase assay 
ATPase activities of activated and non-activated transporters (Pgp, MRP1, MRP2, MRP3, 
BCRP) was measured by using PREDEASY 
TM 
ATPase Kits according to the manufacturer's 
instructions. In brief, membrane vesicles were diluted with assay mix (50 mM Mops-Tris, 50 
mM KCl, 5 mM Na-azide, 2 mM DTT, 0.1 mM EGTA-Tris, 1 mM ouabain in distilled water 
at pH 7.0) to 0.1 µg/µL and a 40 µL aliquote of this dilution was preincubated with one µL of 
tested compound diluted in DMSO with or without sodium orthovanadate (1.2 mM) for 10 
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minutes at 37 °C. Concentration range for tested compounds were 0.39 – 50 µM, 0.32 – 41.4 
µM, 0.25 – 31.4 µM and 0.06 – 8 µM for raloxifene, M1, M2 and M3, respectively. After 
preincubation, the reaction was started by addition of 10 µL of Mg-ATP (0.2 M). The ATPase 
reaction was stopped after 10 min at 37°C and the concentration of liberated inorganic 
phosphate was determined colorimetrically by measuring the absorbance at 600 nm. 
Activation and inhibition experiments were prepared by ATPase assay. For the activation and 
inhibition experiment in addition to listed compounds 2 mM glutathione was used for MRP1, 
MRP2 and MRP3. For the inhibition experiment, ATPase assays were performed in the 
presence of activator substance 40 µM verapamil for Pgp, 10 mM N-ethylmaleimide 
glutathione for MRP1, 100 µM sulfasalazine for MRP2, 50 µM benzbromarone for MRP3 
and 10 µM sulfasalazine for BCRP. Results were calculated using MS Excel 2007. 
 
2.4.2. Membrane vesicular transport studies 
BSEP [23] and MRP2 [24] were expressed in Sf9 and Sf21 cells, respectively using standard 
methodology. Vesicles were isolated from carrier expressing insect cells as described by 
Gerloff et al. [25]. They were resuspended in 50 mM sucrose, 100 mM KNO3, 5 mM 
Mg(NO3)2, 10 mM HEPES/Tris pH 7.4 and stored in liquid nitrogen until use. Uptake 
experiment of 2.5 µM taurocholate into BSEP expressing vesicles and 10 µM E17βG into 
MRP2 expressing vesicles in the presence and absence of 6.25 mM ATP was determined with 
the rapid-filtration methodology. The vesicular transport was terminated at 0 minutes and 10 
minutes and the uptake was calculated first by subtracting the 0 min time point and second by 
subtracting the uptake in the absence of ATP. Raloxifene, M1, M2 and M3 were tested as 
inhibitors of E17βG uptake by MRP2 or BSEP at concentrations of 10, 10, 10, 4 µM, 
respectively. 
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2.5. Liquid chromatography-tandem mass spectrometry conditions  
Caco-2 and PAMPA samples were subjected to LC-MS/MS analysis. The Agilent 1290 
Infinity ultra-high pressure liquid chromatographic system (Agilent Techologies, Santa Clara, 
USA) was coupled to a 6460 Triple Quad Mass Spectrometer (Agilent Techologies, Santa 
Clara, USA). The chromatographic separation was performed on a Kinetex 50 × 2.1 mm 
column with 2.6 µm particles with an In-Line filter KrudKatcher Ultra HPLC 0.5 µm and a 
guard column C18 (2) 4 × 2 mm (Phenomenex, Torrance, USA). The column temperature 
was 50°C. The mobile phase consisted of 0.1% FA in water (mobile phase A) and 98% 
acetonitrile (mobile phase B). The flow rate was set at 0.65 mL/min and the separation 
required a gradient elution. The elution started with 10% of mobile phase B for 0.25 min, and 
then the elution continued with the following gradient: 10%-20%-30%-50%-50%-10% of 
mobile phase B in 0.25-0.50-1.00-1.25-1.70-1.75 min, respectively. The chromatographic 
system was coupled to 6460 Triple Quad Mass Spectrometer with JetStream
TM
 electrospray 
ionization (Agilent Techologies, Santa Clara, USA) operated in positive mode. Instrument 
parameters were set as follows: drying gas temperature 275°C, drying gas flow 5 L/min, 
nebulizer 45 PSI, sheath gas temperature 320°C, sheath gas flow 11 L/min, capillary entrance 
voltage 4000 V, nozzle voltage 1000V, delta EMV 200V. Both quadrupoles Q1 and Q3 were 
set at wide mass resolution and dwell time was 50 ms. Instrument control, data acquisition 
and quantification were performed by MassHunter Workstation software B.03.01 (Agilent 
Technologies, Torrance, USA). The MRM m/z transitions and collision energy characteristics 
for optimal quantification were 474 → 112, 32 eV for raloxifene, 650 → 474, 28 eV for M1 
and M2, 826 → 474, 40 eV for M3 and 376 → 165, 32 eV for haloperidol (internal standard). 
 
2.6. Clinical study 
2.6.1. Study design 
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A total of 57 postmenopausal female patients with osteoporosis were enrolled in the study. 
The inclusion criteria were: osteoporosis (low BMD, T score <-2.5 SD or presence of 
verterbral, femoral or radius fracture), 5 years or more of menopause, and age of less than 70. 
The exclusion criteria were: prior history of venous thromboembolic or malignant disease, 
serious liver or kidney deficiency, smoking, osteoporosis treatment, lipid lowering or 
glucocorticoid treatment, estrogen hormone replacement therapy within 6 months prior to the 
enrolment. The research was carried out according to the principles of the Declaration of 
Helsinki and was in compliance with local regulatory requirements. A written informed 
consent was obtained from each individual and the study protocol was approved by the 
Slovenian National Medical Ethics Committee. The patients were treated for 12 months with 
60 mg raloxifene per day and were followed in the University Medical Centre (Maribor, 
Slovenia). Four patients resigned from the study due to not following the study protocol. 
At baseline, blood was drawn for the measurements of bone turnover markers and DNA 
extraction. All investigations were carried out at 8 a.m. after an overnight fast. After the first 
visit, the participants started with raloxifene 60 mg, cholecalciferol 400 I.U. and calcium 
carbonate 1000 mg daily. Patients did not get any dietary advice. Compliance was checked 
orally by a physician at 3, 6 and 12 months of the therapy. After 12 months, blood was drawn 
for the measurements of bone turnover markers (serum bone-specific alkaline phosphatase 
(BALP), serum osteocalcin (OC), serum C-terminal telopeptide fragments of type I collagen 
(CTX) and concentrations of raloxifene, M1, M2 and M3. After centrifugation, the serum 
samples were stored at -86°C until analysis. The BMD of total hip (BMD-HIP), femoral neck 
(BMD-FN) and lumbar spine L1-L4 (BMD-LS,) and three quantitative ultrasound parameters, 
heel speed of sound (SOS), broadband ultrasound attenuation (BUA) and quantitative 
ultrasound index (QUI) were measured at baseline and after 12 months of raloxifene therapy. 
The statistical power of the study was calculated to be adequate to detect at least 50 % 
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difference in raloxifene species concentrations among the genotype groups with frequencies 
of at least 23%, assuming 50% RSD [9]. Additionally,  the statistical power was calculated to 
be sufficient to detect at least 2% difference in delta BMD after 12 months of treatment in 
different groups with polymorphic genotype frequencies of at least 14% (assuming 50% RSD, 
=0.05, 1-=0.80). 
 
2.6.2. Determination of raloxifene and its metabolites in serum 
The method used for determination of M1, M2 and raloxifene had been developed and 
validated previously in our laboratory and is described in full detail elsewhere [26]. 
Additionally, the metabolite M3 was monitored. In the present study, the selected reaction 
monitoring mode (SRM) set at 826→474 (m/z transition) was used for the quantification of 
M3 using the haloperidol as an internal standard. The limit of detection for M3 was 0.039 nM, 
the limit of quantification was 0.88 nM and the linear range for M3 was from 0.88 nM to 
4800 nM. The intra- and inter- day precisions were 2.4 and 1.3%, respectively. 
TR (total raloxifene) was calculated as a summation of molar concentrations of raloxifene, 
M1, M2 and M3. 
 
2.6.3. Determination of pharmacodynamic parameters 
BMD-HIP, BMD-FN and BMD-LS were determined by dual energy X-ray absorptiometry 
(DXA) with a Hologic QDR-2000+ densitometer (Hologic Inc. Waltham, USA). 
Quantitative ultrasound (QUS) measurements of the calcaneus were performed on the left 
heel of all study participants, with the subject in the sitting position, using a Sahara apparatus 
(Hologic Inc. Waltham, USA). Three QUS parameters of calcaneus were measured: SOS, 
BUA and QUI. An average of two measurements was calculated. 
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BALP was assessed by IRMA (Tandem
®
-R Ostase
®
; Beckman Coulter). OC was measured 
using a two-site immunoluminometric Elecsys N-MID Osteocalcin assay (Roche Diagnostics, 
Mannheim, Germany) [27]. CTX was measured using a two-site immunoluminometric 
Elecsys Beta CrossLaps assay (Roche Diagnostics, Mannheim Germany) [27]. 
  
2.6.4. ABCB1 and ABCC2 genotyping  
Genomic DNA was isolated from peripheral blood leukocytes by using a FlexiGene DNA kit 
(Qiagen, Hilden, Germany). Two SNPs in two different genes c.3435C>T (rs1045642) in the 
ABCB1 gene and c.3972C>T (rs3740066) in the ABCC2 gene were genotyped using validated 
TaqMan Assays (C__7586657_20 and C__11214910_20) from Applied Biosystems in an 
ABI Prism 7000 sequence detection system, under the conditions recommended by the 
manufacturer (Applied Biosystems, Foster City, CA, USA). To validate our results, a random 
selection of 10% of the samples was re-genotyped for each SNP, and the results were found to 
be reproducible with no discrepancies noted. 
 
2.6.5. Statistical analysis 
The Shapiro-Wilk goodness-of-fit test was used to determine the normality of data 
distribution and the Levene’s test was used to test the homogeneity of variances prior to the 
ANOVA and the t-test. A square root transformation was applied to the concentrations of 
raloxifene, M1, M2, M3 and TR in order to obtain a normal data distribution. The Bonferroni 
post hoc test was used to compare the means from genotype groups for each polymorphism. 
The calculation of percentage change of the pharmacodynamic parameters (PD) during 
treatment was calculated according to the Eq. (5).  
%100)(
0
120




parameterPD
parameterPDparameterPD
parameterPD
monthstt
                           Eq. (5) 
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To test the influence of genotype on raloxifene species concentration level and on percentage 
change of pharmacodynamic parameters during treatment, the ANOVA was applied. The 
Hardy-Weinberg equilibrium was tested for each polymorphism using the χ2 test. The 
significance criterion (α) was set at p < 0.05. Data analyses were performed by PASW 18.0 
software (IBM company, Illinois, Chicago, USA). 
 
3. Results 
3.1.   Passive permeability measurements  
The passive part of raloxifene species permeability was assessed with a PAMPA model. The 
rank order of the compound permeability through the PAMPA membrane shows that 
raloxifene has the highest passive permeability, followed by raloxifene monoglucuronides and 
M3, with the lowest passive permeability (Table 1).  
 
3.2. Transcellular transport assay 
Caco-2 cell monolayers were used for the identification of transporters involved in raloxifene 
transport and for the determination of absorptive raloxifene permeability. The results indicate 
a decrease in raloxifene efflux ratio, when verapamil (Pgp inhibitor) [22] was applied to the 
apical side. Fum C (BCRP inhibitor) [28] and MK571 (MRP inhibitor) [29] did not cause any 
significant changes in the efflux ratio (Table 2). Contrary to the previously published results 
by Jeong et al. [12], we did not observe any raloxifene glucuronides nor sulfates formation on 
either donor or acceptor sides.  
 
3.3. ATPase assay 
The results of activation and inhibition experiments on transporter ATPases are presented in 
Tables 3 A and 3 B. It has been previously documented that the modulation of ABC 
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transporter-specific ATP hydrolysis by a given test compound is a clear sign of its interaction 
with the protein [30]. The results of activation and inhibition tests for raloxifene, M1, M2 and 
M3 are shown in Tables 3 A and 3 B. In the activation experiment raloxifene and M3 
activated the utilization of ATP by Pgp to promote the transport of these two raloxifene 
species across the membrane. The utilization of ATP was increased also in the case of M3 
when it was incubated with MRP1 membranes. Raloxifene, M1 and M2 increased the 
utilization of ATP by MRP3. When the tested raloxifene species were incubated with BCRP 
vesicles there was no change in ATP hydrolysis. In the inhibition experiment an inhibition of 
activated ATPase activity was observed in all cases except when incubating M1 with MRP2 
membranes. 
 
3.4. Vesicular transport (BSEP, MRP2) 
Fig. 1 shows the uptake of E17βG as a typical substrate for MRP2 in the absence and 
presence of raloxifene species as inhibitors. It was observed that M2 and M3, but not M1 and 
raloxifene significantly inhibited the uptake of E17βG. On the contrary, no inhibition of 
taurocholate as a typical BSEP substrate was observed in incubation of raloxifene species 
with BSEP vesicles (data not shown). 
 
3.5. Patient's genotype frequencies 
Patient's genotype frequencies for the ABCB1 c.3435C>T and ABCC2 c.3972C>T 
polymorphisms are shown in Table 4. The tested polymorphisms were chosen on the basis of 
variant allele frequencies that were 46.0%, 32.1% and 9.5% for ABCB1 c.3435C>T [31],  
ABCC2 c.3972C>T [18] and ABCG2 c. 421C>A [32], respectively. Due to a relatively small 
number of study participants and low allelic frequency the genotyping for ABCG2 c. 421C>A 
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was not performed. All genotype frequencies were found to be in Hardy-Weinberg 
equilibrium (p>0.05). 
 
3.6. Effect of ABCB1 c.3435C>T and ABCC2 c.3972C>T on plasma concentration of 
raloxifene species 
The effect of ABCB1 c.3435C>T and ABCC2 c.3972C>T polymorphisms on plasma 
concentration of raloxifene, M1, M2 and M3 was not found to be significant. The ABCB1 
3435CT and TT variants exhibited a trend toward increased serum concentrations of all tested 
raloxifene species over homozygous wild-type, but did not reach statistical significance 
(Table 5). 
 
3.7. Effects of ABCB1 c.3435C>T and ABCC2 c.3972C>T on pharmacodynamic 
parameters 
A significant difference in percent change in BMD-HIP after 1 year of raloxifene treatment 
was observed in subjects according to the ABCB1 c.3435C>T polymorphism. Patients 
homozygous for the T allele compared with the heterozygote and the wild-type experienced a 
higher increase in BMD-HIP after 1 year (Table 6). On the other hand, the changes in BMD-
LS and BMD-FN and changes in bone turnover markers were not significant. 
 
4. Discussion 
The main goal of our study was to determine which excretory transporters may play a 
significant role in the disposition of raloxifene and may also be involved in the observed 
variability in raloxifene exposure and therapeutic effect. Complex in vitro and in vivo 
approaches have been utilized to comprehensively describe the excretory transport of 
raloxifene and its conjugates. We have shown a strong in vitro evidence of raloxifene species 
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interaction with Pgp and MRP transporters which encouraged us to perform an in vivo study 
to evaluate the influence of genetic polymorphisms of these two transporters on both 
raloxifene pharmacokinetics and pharmacodynamics. 
 Although raloxifene conjugates do not bind with estrogen receptors with affinity high enough 
to evoke a pharmacological response they are considered as carriers of active raloxifene [9, 
10]. Their blood serum concentration is more than hundred times higher than raloxifene serum 
concentration (Table 5) and they can be cleaved back to parent raloxifene in many tissues and 
organs [7, 10]. Therefore, in order to elucidate the complex raloxifene disposition it is vital to 
understand raloxifene glucuronide membrane transport and its effect on both raloxifene 
pharmacokinetics and pharmacodynamics. 
First, PAMPA was used to predict the passive transcellular permeability of raloxifene, M1, 
M2 and M3. Secondly, a cell based transport assay for the possible involvement of Pgp, MRP 
and BCRP was performed on Caco2 cells. Thirdly, two types of membrane-based assays were 
performed: ATPase assay for Pgp, MRP1, MRP2, MRP3 and BCRP and vesicular transport 
assay for BSEP and MRP2. Finally, an in vivo study on postmenopausal women with 
osteoporosis was undertaken to test the clinical significance of genetic polymorphisms in 
genes coding for Pgp and MRP2, which were found to interact either with raloxifene or its 
glucuronides.  
As expected, the PAMPA experiments showed significant differences in passive permeability 
coefficients of raloxifene species. Raloxifene permeability was the highest, followed by its 
more hydrophilic metabolites M1, M2 and M3. From these results it is clear that raloxifene 
conjugates require an active or facilitated transport to efficiently cross the biological 
membranes. The Caco2 cell line was used for further permeability studies to reveal the 
possible participation of membrane transporters during the raloxifene absorption phase. The 
measured raloxifene Caco2 permeability was higher than reported permeability of estradiol 
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and lower than reported permeability of tamoxifen (7.9 ± 1.1 vs 1.2 ± 0.8 vs 47.4 ± 21.0 [*10-6 
cm/s] , respectively) [33, 34]. The obtained efflux ratio for raloxifene (ER) of 11.7 (Table 2) 
showed that raloxifene is actively excreted from the Caco2 cells, while a significant drop of 
ER to 6.2 observed in the presence of verapamil (a Pgp inhibitor) suggests that raloxifene 
excretion from Caco2 cells is largely mediated by Pgp, which is in accordance with findings 
of Jeong et al. [12] and Chang et al. [11]. On the other hand, no significant changes in efflux 
ratio were detected with either the MRP or BCRP inhibitors. Caco2 transport experiments 
with raloxifene conjugates (M1, M2, M3) could not be performed due to the limited amounts 
of synthesized standards. To investigate the interactions between raloxifene species and 
individual transporters, the ATP-ase membrane assays and inside-out membrane vesicles were 
performed, which consumed lesser amounts of metabolite standards. The modulation of ABC 
transporter-specific ATP hydrolysis by a test compound was taken as a sign of its interaction 
with the studied transporter. ATP-ase activation suggested the presence of an actively 
transported compound, while an inhibition of activated transporter (in a separate experiment) 
indicated a low transport rate or a direct inhibition of the transporter. The results from 
membrane preparations were complex and rather difficult to interpret. However, it is safe to 
assume the following conclusions: raloxifene is a Pgp substrate because of the positive results 
on Caco2 with verapamil and weak activation and strong inhibition of Pgp ATP-ase. 
Furthermore, M2 and M3 could be MRP2 substrates or inhibitors because of the observed 
inhibition and activation of MRP2 ATP-ase and significant inhibition of E17βG vesicular 
uptake. Moreover, there were significant activation and/or inhibition interactions detected 
between raloxifene species and MRP1 and MRP3 transporters. Therefore it was deemed 
reasonable to expect a significant influence of the studied transporters on raloxifene 
disposition. To determine the in vivo effects of efflux transporters’ genetic polymorphisms, a 
clinical study on postmenopausal women with osteoporosis was undertaken. Serum 
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concentrations of raloxifene, M1, M2 and M3 were determined using a validated LC-MS/MS 
method. Patients were genotyped for ABCB1 c.3435C>T and ABCC2 c.3972C>T and it was 
found that none of the tested polymorphisms significantly influenced the serum 
concentrations of raloxifene species. However, in the case of ABCB1 c.3435C>T a trend 
towards higher concentrations of raloxifene species in patients with at least one polymorphic 
allele was observed but due to an unexpectedly high interindividual variability it was not 
significant. The observed polymorphism effect of higher raloxifene species concentrations 
could be explained by a lower Pgp expression levels in both liver and intestine in carriers of 
polymorphic alleles leading to a decreased raloxifene species excretion and consequently to 
their higher serum levels. This explanation is in accordance with the previous results obtained 
by Hoffmeyer et al. [13] where it was postulated that individuals homozygous for this 
polymorphism had significantly lower MDR1 expression levels and dysfunction of MDR1. 
Furthermore, raloxifene is extensively conjugated in both enterocytes and hepatocytes to its 
metabolites. Consequently, a decreased Pgp activity would also increase raloxifene exposure 
to the UGTs, therefore this may explain why the concentrations of raloxifene metabolites in 
serum tended to be higher in patients with polymorphic MDR1. 
Besides the pharmacokinetic changes, we also evaluated the percent change in 
pharmacodynamic parameters after 1 year of raloxifene treatment. It was discovered that 
ABCB1 c.3435C>T polymorphism significantly influenced the percent change of BMD-HIP 
after 12 months of raloxifene treatment.  Based on the results (Table 6), individuals 
homozygous for the c.3435T variant experienced a significantly higher increase in BMD-HIP 
than the wild-type homozygotes. This is in accordance with the observed trend of higher 
concentrations of raloxifene species in patients with ABCB1 c.3435TT genotype.  To further 
explore the connection between raloxifene efficacy and safety profile with the presence of the 
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relatively frequent c. ABCB1 3435C>T polymorphism, it would be advisable to conduct a 
larger prospective cohort study. 
In conclusion, we discovered which transporters are most likely involved in the excretion of 
raloxifene species into bile, which is a very important step in the enterohepatic recirculation 
of raloxifene and therefore an important determinant for the overall raloxifene exposure. The 
presented data implicate that at least a part of the observed variability could be explained by 
the genetic influence of ABCB1 c.3435C>T polymorphism. In this study, the synergistic use 
of in vitro models combined with a small in vivo study has proven to be successful in 
identification of relevant transporters and confirmation of their in vivo effects. The presented 
multidisciplinary approach of translational research yielded an insight into complex 
mechanisms of raloxifene disposition and the gained knowledge may thus insure a safer and 
more effective treatment strategy in the clinical setting. 
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Legends for figures 
Fig. 1: Inhibitory effects of raloxifene, raloxifene-6-β-glucuronide (M1), raloxifene-4'-β-
glucuronide (M2), raloxifene-6,4'-diglucuronide (M3) on active uptake of estradiol-17β-
glucuronide (E17βG) into MRP2 expressing membrane vesicles. Each column represents the 
mean (SE) (n=4) and (*) indicates a significant difference from the control (p < 0.05). 
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Click here to download high resolution image
Table 1 
Passive permeability of raloxifene species. 
 Papp (*10
-7
 cm/s) 
RAL 27.0 ± 8.0 
M1 1.4 ± 0.17 
M2 0.88 ± 0.15 
M3 0.51 ± 0.007 
The values in table are presented as mean (±standard deviation). 
RAL, raloxifene; M1, raloxifene-6-β-glucuronide; M2, raloxifene-4'- β-glucuronide; M3, raloxifene-6,4'- diglucuronide 
 
Table1
Table 2 
 The influence of specific inhibitors of transporters on efflux ratio of raloxifene 
Caco-2 permeability (*10
-6
 cm/s) 
Inbibitor AP-BL BL-AP ER S/NS 
reference 7.9 ± 1.1 11.7 ± 1.6 1.48 ± 0.29  
Ver [100µM] 13.1 ± 1.0 6.2 ± 0.9 0.47 ± 0.08 S 
MK [25µM] 9.2 ± 1.8 10.3 ± 2.7 1.12 ± 0.37 NS 
FumC [10µM] 8.2 ± 1.1 8.4 ± 1.7 1.02 ± 0.25 NS 
The ER values represent the ratio between BL–AP (basolateral-apical) and AP–BL(apical-basolateral) permeabilities of 
raloxifene. The values in table are presented as mean (±standard deviation). 
S/NS statistical analysis of ER (efflux ratio) change comparing with reference, S significant (p<0.05), NS not 
significant (p>0.05). Ver, verapamil; MK, MK571; FumC, fumitremorgin C. 
 
Table2
Table 3A 
Quantitative ATPase assay results obtained in baseline, activation and inhibition experiments 
Averages of released Pi at baseline / activation / inhibition experiments 
[nmol/mg(protein)/min] 
 Pgp MRP1 MRP2 MRP3 BCRP 
RAL 11.5/34.4/7.3 9.9/14.9/0.9 5.9/10.9/-1.4 3.7/15.3/2.5 2.8/12.3/-19.9 
M1 20.3/47.2/14.5 13.2/17.1/-0.1 7.9/18.1/-1.5 13.5/22.3/6.8 5.0/25.7/-15.0 
M2 14.8/43.5/7.8 10.9/14.5/-1.4 7.6/20.2/0.2 10.2/20.0/8.4 5.2/15.6/-20.3 
M3 10.9/48.5/11.5 8.1/18.6/0.7 7.5/16.7/-0.9 4.4/12.4/2.4 8.6/31.4/-15.7 
Estimated IC50 values* 
[µM] 
RAL 6 5 2 12 6 
M1 10 1 n.d.** 10 40 
M2 6 4 1.5 8 0.25 
M3 0.75 2 nd** 0.5 3 
 
* IC50 values were estimated from ATP dependent transport curves versus raloxifene 
species concentrations (figures not shown). 
** the slope of the concentration-ATP-ase inhibition curve was not significantly 
different from 0 
 
Table3a
Table 3 B 
Presentation of ATPase assay results 
Activation experiment 
 Pgp MRP1 MRP2 MRP3 BCRP 
RAL + n.e. n.e. + n.e. 
M1 n.e. n.e. n.e. + n.e. 
M2 n.e. n.e. n.e. + n.e. 
M3 + + n.e. n.e. n.e. 
Inhibition experiment 
 Pgp MRP1 MRP2 MRP3 BCRP 
RAL -- -- -- - -- 
M1 - -- n.e. - - 
M2 -- -- -- -- -- 
M3 - - - - - 
+   weak activation 
++   strong activation (was not detected) 
-   weak inhibition 
--   strong inhibition 
n.e.…no effect 
RAL, raloxifene; M1, raloxifene-6-β-glucuronide; M2, raloxifene-4'-β-glucuronide; M3, raloxifene-6,4'-diglucuronide 
 
Table3b
Table 4 
Genotype frequencies of ABCB1 and ABCC2 polymorphisms 
Genetic variant Genotype 
Number of 
patients 
Frequency (%) 
ABCB1 
c.3435C>T 
CC 17 29.8 
CT 24 42.1 
TT 16 28.1 
ABCC2 
c.3972C>T 
CC 26 45.6 
CT 21 36.8 
TT 10 17.5 
 
Table4
Table 5 
Summary of concentration of raloxifene species according to ABCB1 c.3435C>T and ABCC2 
c.3972C>T polymorphisms 
 ABCB1 c.3435C>T  ABCC2 c.3972C>T 
 CC CT TT 
p value 
(ANOVA) 
 CC CT TT 
p value 
(ANOVA) 
c (M1) 
(nmol/L) 
49 
(10) 
83 
(14) 
79 
(23) 
0.170 
 58 
(9) 
94 
(20) 
50 
(11) 
0.282 
c (M2) 
(nmol/L) 
199 
(42) 
402 
(77) 
347 
(90) 
0.090 
 270 
(53) 
424 
(86) 
206 
(48) 
0.344 
c (M3) 
(nmol/L) 
301 
(59) 
582 
(107) 
675 
(270) 
0.173 
 333 
(53) 
711 
(202) 
529 
(197) 
0.192 
c (RAL) 
(nmol/L) 
2.8 
(0.4) 
4.3 
(0.7) 
3.6 
(0.9) 
0.377 
 3.6 
(0.5) 
3.4 
(0.6) 
4.0 
(1.4) 
0.976 
c (TR) 
(nmol/L) 
552 
(99) 
1071 
(171) 
1105 
(360) 
0.111 
 665 
(105) 
1232 
(279) 
789 
(251) 
0.232 
The values of concentrations are presented as means (standard errors). 
RAL, raloxifene; M1, raloxifene-6-β-glucuronide; M2, raloxifene-4'-β–glucuronide; M3, raloxifene-6,4'-di–glucuronide; TR, 
total raloxifene 
 
Table5
Table 6 
Percentage change of bone mineral density of total hip according to the presence of ABCB1 
c.3435C>T polymorphism after 12 months of raloxifene treatment in 53 postmenopausal 
women. 
 ABCB1 c.3435C>T  ABCC2 c.3972C>T 
 CC CT TT 
p value 
(ANOVA) 
 CC CT TT 
p value 
(ANOVA) 
Δ BMD-
HIP (%) 
-2.1 
(2.5) 
-0.5 
(0.9) 
6.5 
(3.0) 
0.016
a
 
 0.03 
(2.4) 
2.2 
(1.8) 
-2.1 
(1.7) 
0.809 
Δ BMD-
LS (%) 
0.6 
(1.1) 
2.5 
(1.0) 
1.3 
(1.4) 
0.523 
 1.4 
(1.1) 
1.7 
(0.9) 
2.0 
(1.5) 
0.608 
Δ BMD-
FN (%) 
0.2 
(1.3) 
2.3 
(0.9) 
1.3 
(1.7) 
0.589 
 2.3 
(0.9) 
0.4 
(1.0) 
0.8 
(2.5) 
0.269 
Δ BUA 
(%) 
-1.0 
(2.2) 
2.3 
(1.7) 
5.9 
(2.4) 
0.399 
 1.5 
(1.6) 
1.4 
(2.0) 
5.9 
(3.6) 
0.431 
Δ SOS 
(%) 
-0.03 
(0.15) 
-0.09 
(0.19) 
0.12 
(0.11) 
0.230 
 -0.02 
(0.16) 
0.09 
(0.17) 
-0.22 
(0.15) 
0.660 
Δ QUI 
(%) 
-0.2 
(1.5) 
-0.2 
(2.0) 
2.8 
(1.1) 
0.283 
 0.3 
(1.4) 
1.8 
(2.1) 
-0.05 
(1.8) 
0.840 
Δ BALP 
(%) 
-24.3 
(6.3) 
-16.9 
(8.3) 
-29.9 
(3.9) 
0.434 
 -29.0 
(4.8) 
-13.6 
(9.2) 
-22.5 
(8.2) 
0.269 
Δ OC 
(%) 
-24.1 
(5.3) 
-28.2 
(4.5) 
-22.6 
(4.2) 
0.770 
 -23.5 
(3.9) 
-27.5 
(5.3) 
-27.2 
(5.1) 
0.635 
Δ CTX 
(%) 
-22.9 
(7.5) 
-32.0 
(5.8) 
-18.9 
(8.1) 
0.601 
 -18.1 
(6.2) 
-37.4 
(4.9) 
-23.5 
(10.5) 
0.315 
Table6
The values are presented as means (standard errors). 
a
p(1,3)=0.024 
 
